Literature DB >> 4528634

Long-term desferrioxamine therapy in thalassemia.

C B Modell, J Beck.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4528634     DOI: 10.1111/j.1749-6632.1974.tb20586.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  16 in total

1.  Editorial: Blood transfusion and iron overload.

Authors: 
Journal:  Br Med J       Date:  1975-11-01

2.  Total management of thalassaemia major.

Authors:  B Modell
Journal:  Arch Dis Child       Date:  1977-06       Impact factor: 3.791

3.  Haemoglobinopathies. The pathophysiology of beta-thalassaemia major.

Authors:  C B Modell
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1974

Review 4.  Current concepts in the management of thalassemia.

Authors:  R S Festa
Journal:  Indian J Pediatr       Date:  1987 May-Jun       Impact factor: 1.967

5.  Intensive iron-chelation in thalassaemia.

Authors: 
Journal:  Br Med J       Date:  1978-09-16

6.  Survival and desferrioxamine in thalassaemia major.

Authors:  B Modell; E A Letsky; D M Flynn; R Peto; D J Weatherall
Journal:  Br Med J (Clin Res Ed)       Date:  1982-04-10

7.  Early iron overload in beta-thalassaemia major: when to start chelation therapy?

Authors:  S Fargion; M T Taddei; V Gabutti; A Piga; A Di Palma; L Capra; G Fontanelli; A Avanzini
Journal:  Arch Dis Child       Date:  1982-12       Impact factor: 3.791

8.  Iron-mediated oxidative stress in erythrocytes.

Authors:  C Rice-Evans; E Baysal
Journal:  Biochem J       Date:  1987-05-15       Impact factor: 3.857

9.  Tinnitus in a patient with beta-thalassaemia intermedia on long-term treatment with desferrioxamine.

Authors:  M N Marsh; I B Holbrook; C Clark; J L Shaffer
Journal:  Postgrad Med J       Date:  1981-09       Impact factor: 2.401

10.  Desferrioxamine in ocular siderosis: a long-term electrophysiological evaluation.

Authors:  S S Declercq
Journal:  Br J Ophthalmol       Date:  1980-08       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.